Novo Nordisk Pharmatech

Activities: Ingredients Research & Development

Trending Articles

  1. SPT Labtech and Cavendish combine technologies to improve the cell-based assay design process By combining technologies, the companies hope to optimise the cell assay development workflow with automation
  2. Hongene Biotech to manufacture Hangzhou Biotech's siRNA-based dyslipidaemia therapy The CDMO will manufacture raw materials for the clinical development of DNV001, a novel therapy for the treatment of dyslipidaemia
  3. Univercells and Repligen join forces to optimise the real-time monitoring of biologic production By performing real-time monitoring in bioreactors, the companies will eliminate the need for manual nutrient testing when growing cell cultures
  4. Pila Pharma bags nearly £1.5m to aid obesity drug development The ex-Novo Nordisk researcher-founded biotech will use the money to expand its obesity clinical pipeline
  5. Ofichem Group to acquire drug formulation development specialist, Avivia Ofichem will now be able to offer its clients a range of early-stage development services, from analytical method development to excipient characterisation

Upcoming event

POWTECH

23-25 September 2025 | Exhibition | Nuremberg, Germany See all

Related Content

Research & Development

Novo Nordisk's Wegovy effective in obese patients, Phase IIIb data suggests

A 7.2mg dose of semaglutide triggered an average weight loss of 21% in obese patients during a 72 week period
Finance

Weight loss drugs fuelling rapid big pharma growth, report reveals

Weight loss and diabetes medications are championing growth in key big pharma players, such as Novo Nordisk and Eli Lilly
Finance

Novo Holdings completes acquisition of Catalent

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
Manufacturing

Novo Nordisk invests DKK 8.5bn into new Danish modular production site

This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
Manufacturing

Novavax sells protein manufacturing facility to Novo Nordisk for $200m

Novo Nordisk's purchase of Novavax's Czech recombinant protein manufacturing facility will involve a full transfer of assets — including its workforce and associated support buildings
Manufacturing

Novo Nordisk acquires license to Ascendis Pharma's TransCon tech for up to $286m

Novo Nordisk will use the technology to develop, manufacture and commercialise therapeutics for metabolic and cardiovascular diseases
Regulatory

Novo Nordisk's haemophilia A/B drug Alhemo gets positive opinion from the EMA

The subcutaneous, self-administering prophylactic can allow a patient to produce thrombin, a clotting agent, even in the presence of inhibitors
Subscribe now